PSA testing is an important tool to spot prostate cancer, but it remains a bit confusing. Stanford urologist James Brooks clarifies some misconceptions.
A team of Stanford scientists have devised a new imaging technology that harnesses ultrasound and photoacoustics to detect prostate cancer earlier.
Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.
The U.S. Preventive Services Task Force is now recommending that men aged 55 to 69 should talk with their doctors about prostate-specific antigen screening.